Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK129885)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125459)
National Heart, Lung, and Blood Institute (R01HL145528)
- License Information
-
More Information
Article History
Received: 24 November 2025
Revised: 9 February 2026
Accepted: 2 March 2026
First Online: 30 March 2026
Declarations
:
: C.F. has served as consultant for Bayer and Calico Labs. C.F. is an inventor on two pending patents (PCT/US2019/049211; PCT/US19/49161), and he has a patent on FGFR inhibition (European Patent No. 2723391). C.F. is the co-founder and CSO of a startup biotech company (Alpha Young LLC). C.F. received honoraria for publishing a book (“FGF23”, Elsevier, ISBN9780128180365). T.M., V.V. and A.F. declare that there is no competing interest.
